Informazioni
Non ci sono recensioni
Punto di Riferimento
per Medici e Operatori Sanitari
per Medici e Operatori Sanitari
LIBRERIA STUDIUM
Blood and Marrow Transplantation Long Term Management, 2nd Edition
Survivorship after Transplant
Savani, Tichelli
Editore
Wiley
Anno
2021
Pagine
464
ISBN
9781119612698
141,00 €
DA SCONTARE
Blood and Marrow Transplantation Long Term Management
Hematopoietic cell transplantation (HCT) provides curative therapy for a variety of diseases. Over the past several decades, significant advances have been made in the field of HCT, to the point where HCT has become an integral part of treatment modality for a variety of hematologic malignancies and some nonmalignant diseases. HCT remains an important treatment option for a wide variety of hematologic and nonhematologic disorders, despite recent advances in the field of immunologic therapies. Factors driving this growth include expanded disease indications, greater donor options (expanding unrelated donor registries and haploidentical HCT), and accommodation of older and less fit recipients.
The development of less toxic pretransplant conditioning regimens, more effective prophylaxis of graft-versus-host disease (GVHD), improved infection control, and other advances in transplant technology have resulted in a rapidly growing number of transplant recipients surviving long-term free of the disease for which they were transplanted. The changes over decades in the transplant recipient population and in the practice of HCT will have almost inevitably altered the composition of the long-term survivor population over time. Apart from an increasingly older transplant recipient cohort, the pattern of transplant indications has shifted from the 1990s when chronic myeloid leukemia made up a significant proportion of allo-HCT indications. Changes in cell source, donor types, conditioning regimens, GVHD prophylaxis, and supportive care have all occurred, with ongoing reductions in both relapse and non-relapse mortality (NRM) have been demonstrated.
These patients have increased risks for a variety of late complications, which can cause morbidity and mortality. Most long-term survivors return to the care of their local hematologists/oncologists or primary care physicians, who may not be familiar with specialized monitoring and management of long complications after HCT for this patient population. As HCT survivorship increases, the focus of care has shifted to the identification and treatment of long-term complications that may affect quality of life and long-term morbidity and mortality.
Preventive care as well as early detection and treatments are important aspects to reducing morbidity and mortality in long-term survivors after allo-HCT. This second edition, Blood and Marrow Transplantation Long Term Management: Survivorship after Transplant, provides up-to-date information about diagnosis, screening, treatment, and long-term surveillance of long-term survivors after HCT.
List of contributors
Section 1 Late effects concepts
1 Introduction
Bipin N Savani and Andre Tichelli
2 International Blood and Marrow registries – trends on long-term data collection
Rachel Phelan, Jakob Passweg, Helen Baldomero, Minako Iida, Yoshiko Atsuta, Shinichiro Okamoto, Mahmoud Aljurf, Feras Alfraih, and Bronwen Shaw
3 Long-term transplant clinic setup
André Tichelli, Bipin Savani, Shahrukh K Hashmi, Navneet S Majhail, and Alicia Rovó
4 Telemedicine in patient care of long-term survivors
Catherine Lee, Mihkaila Wickline, and Mary Flowers
5 Long-term follow-up calendar
André Tichelli, Bipin N Savani, Shahrukh K Hashmi, Navneet S Majhail, and Alicia Rovó
6 Late effects after allogeneic hematopoietic stem cell transplantation
Shahrukh Hashmi and Yoshihiro Inamoto
7 Late effects after autologous hematopoietic stem cell transplantation
Rajshekhar Chakraborty and Betty Hamilton
8 Long-term follow-up of children
Paul Carpenter
9 Graft-versus-host disease and GvHD-associated late effects
David Michonneau, Aurélien Sutra-del-Galy, and Gérard Socié
10 Screening and prevention guidelines for hematopoietic cell transplant survivors
Neel S Batt, J Douglas Rizzo, and Navneet S Majhail
11 Biology of survivorship after BMT
Smita Bhatia
Section 2 Specific late effects
12 Secondary malignancies
Aurélien Sutra-del-Galy, David Michonneau, and Gérard Socié
13 Anti-infective prophylaxis, immunization and prevention of late infectious complications
Per Ljungman
14 Seasonal virus infections in recipients and exposure to family members
Nosha Farhadfar, Zeina Al-Mansour, and John Wingard
15 Monitoring and management of hepatitis B, C, and HIV infection before and after transplantation
Enric Carreras and Montserrat Rovira
16 Skin chronic graft-versus-host disease
Attilio Oliveri and Andrea Bacigalupo
17 Ocular complications
Alicia Rovó, André Tichelli, and Yoshihiro Inamoto
18 Oral and dental complications
Hildegard Greinix
19 Thyroid late complications
Juliana Matthews, Leslee Matheny, and Shubhada Jagasia
20 Pre-transplant considerations in gender, reproductive, and sexual health
Dana Shanis, Jeanne Murphy, Kate Debiec, Betty K Hamilton, Shawna Boyle, and Pamela Stratton
21 Post-transplant considerations in gender, reproductive, and sexual health
Jeanne Murphy, Dana Shanis, Kate Debiec, Betty K Hamilton, Shawna Boyle, and Pamela Stratton
22 Fertility issues, fertility preservation, and pregnancy outcome in long-term survivors
Alicia Rovó, Alison W Loren, André Tichelli, and Nina Salooja
23 Sexual dysfunction in long-term survivors
Rebecca Hunter, Sarah Thilges, Janna Gordon, Kristy Luke, Karla Cavazos, Emilee Moeke, Colleen Bruen, and Sunita Natha
24 Non-infectious pulmonary late complications
Ayman O Soubani
25 Cardiac and arterial complications
Alicia Rovó and André Tichelli
26 Cardiovascular risk factors
Kimberley Doucette and Minoo Battiwalla
27 Gastrointestinal complications
Sumona Bhattacharya, Steven Pavletic and Theo Heller
28 Hepatic complications
Christy Ann L Gilman Christopher Koh, Steven Pavletic, and Theo Heller
29 Renal complications
Insara Jaffer Sathick, and Sangeeta Hingorani
30 Post-Transplantation Bone Disease
Christine Ducan
31 Neurological late complications
Enrico Maffini
32 Neurogognitive dysfunction
David Buchbinder
33 Psychological distress
Anna Barata, Aasha I Hoogland and Heather SL Jim
34 Persistent chronic fatigue
Sandy Mitchell
35 Social issues
Sanghee Hong and Navneet Majhail
36 Health-related quality of life in adult and pediatric survivors
Lori Wiener, Jenny Hoag, and Tamryn Gray
Section 3 Supportive care and patients reported outcome
37 Immunosuppressive agents and monitoring in long-term survivors
Katie Culos and Katie Gatwood
38 Nutritional support and nutritional supplementation
Shigeo Fuji
39 Daily routines and healthy lifestyle guidelines
Melissa Logue
40 Prevalent psychosocial adjustment issues and solutions: lifestyle and social challenges
Katrina Stokes
41 Complementary and alternative medicine in HSCT
Ibrahim N Muhsen, Bipin N Savani, and Shahrukh Hashmi
42 Impact of adherence in outcome of long-term survivors
Corien Eeltink and Annika Kisch
43 Prominent role of allied health professionals
Catherine E Lucid
44 Patient reported outcome
Hélène Schoemans
45 Caregivers of long-term survivors
Angela Moreschi Woods
46 Patient’s perspective: memory of a recovered lymphomaniac
Michael Brown
Appendix 1 Commonly used transplant-related medications in long-term survivors
Katie Culos and Katie Gatwood
Appendix 2 The eGVHD App
Hélène Schoemans
Index
